The Independent Medication Review looks at your whole medication list. This page explains what it covers for blood pressure medication: whether each one remains clinically appropriate, and a safe, monitored step-down plan where the evidence supports it.
Not sure why you have high blood pressure in the first place? Start with the investigation page →
Investigations are charged separately.
Blood pressure medication is initiated under a specific set of clinical circumstances. Those circumstances change. Weight changes. Lifestyle changes. Other medications change. The reason the prescription was written in the first place may no longer apply. But the repeat prescription keeps printing.
A 10-minute GP appointment is not enough to properly assess whether a medication started five years ago still makes sense for who you are today. That assessment is part of the Independent Medication Review.
The outcome is not always to stop the medication. Sometimes the outcome is continue, with reassurance and a clear clinical reason. But you deserve to know which one applies to you, and why.
Stopping blood pressure medication abruptly is not safe. Some antihypertensives, particularly beta-blockers and centrally acting agents, carry real rebound risks if discontinued without a structured taper. Even those without pharmacological rebound risk require monitoring as the dose reduces, because blood pressure can rise before the body re-equilibrates.
That is the clinical problem most patients face. They know something has changed. They sense the medication may no longer be right. But they cannot simply stop, and their GP appointment doesn't have time for a proper review.
The review covers that gap as part of going through your whole list: a systematic assessment of whether step-down is appropriate, followed by a specific taper plan with monitoring targets and clear decision rules if readings rise.
Abrupt discontinuation of some antihypertensives, particularly beta-blockers and clonidine, can cause BP to spike above the original reading. Structured tapering prevents this.
Different medications require different step-down speeds. Amlodipine has a long half-life and tapers slowly. Beta-blockers require careful graduated reduction. A plan that works for one drug may not be appropriate for another.
Clinic readings are a single snapshot. A safe step-down requires consistent home monitoring: specific targets, specific times, and a clear threshold that prompts review.
If the original cause of elevated BP has been addressed (weight loss, sleep apnoea treatment, stopping an offending medication), the case for step-down is much stronger. If it hasn't, step-down requires more caution.
Each class has a different mechanism, a different step-down approach, and a different rebound risk profile. The review looks at whichever of these you are on, alongside everything else on your list.
Generally well-tolerated but commonly associated with a persistent dry cough. Step-down is usually straightforward with dose reduction and home monitoring. Sometimes appropriate to switch to an ARB rather than discontinue entirely.
Similar mechanism to ACE inhibitors without the cough side effect. Often initiated as an alternative. Step-down follows a similar graduated approach with monitoring of BP and renal function.
Long half-life means slower accumulation and slower clearance. Step-down is gradual. Ankle swelling is a common side effect that often resolves on dose reduction, a frequent reason patients seek review. What the review considers for amlodipine →
Require the most careful step-down of all antihypertensive classes. Abrupt discontinuation can cause rebound tachycardia and hypertension. Dose reduction must be gradual, typically over weeks to months.
Often added as a third agent. Electrolyte monitoring, particularly potassium, is important during step-down. Can cause fatigue, muscle cramps, and impotence at higher doses, which are frequently underreported.
Less commonly used as first-line but frequently encountered in polypharmacy. Clonidine in particular carries significant rebound risk and requires very gradual, carefully monitored discontinuation.
Understanding the underlying drivers of your hypertension is an important part of any step-down decision. If the original cause has been addressed, the case for reducing medication is significantly stronger. If it hasn't, the step-down plan needs to account for that. The blood pressure investigation page covers this in detail, including the drivers most people are never tested for.
Safe medication step-down requires review, a specific plan, monitoring, and a clear pathway if something changes. This is what that looks like.
Current medication list, home BP readings, clinic readings, relevant blood results, lifestyle changes since the medication was started, and any side effects being experienced.
Is step-down clinically appropriate? What has changed? What does the current BP picture show? What is the risk of stepping down versus continuing? This is the core clinical question the review answers.
A specific, stepwise reduction schedule: which medication, which dose, at what intervals, with what home monitoring targets. Written and yours to keep.
A summary to your GP where appropriate. Clear decision rules for what readings would prompt a review of the plan. Follow-up available if something changes.
Blood pressure medication should never be stopped abruptly without clinical supervision. Every plan is built around safety first.
For blood pressure medication, the written plan from your review sets out the following, so you can follow it and share it with your GP.
Continue, reduce, switch, or step down, with the clinical reasoning clearly documented.
A specific dose reduction schedule with timeframes: which medication, which dose, at which intervals.
Specific readings to aim for, when to measure, and what variation is expected and acceptable.
Clear thresholds: specific readings that would prompt a review of the plan or a return to the previous dose.
A written summary to your GP where appropriate, keeping your prescribing care coordinated.
A clear route back if something changes. If the plan needs watching while you carry it out, supervised step-down is there for that.
Blood pressure medication is reviewed as part of the Independent Medication Review, alongside everything else you take.
A 55-minute consultation in person and your written plan. Supervised step-down while you carry the plan out is £99 a month, if you want it: a short check each month, your home readings reviewed, a letter to your GP each time a dose changes, and email in between. It ends when the plan is complete.
Investigations are charged separately, whether they are done privately or through your GP. Supervised step-down is set up after your consultation, not at booking. New or urgent symptoms go to your GP, NHS 111 or 999.
The Independent Medication Review assesses whether your blood pressure medication, and everything else you take, remains the right clinical decision, and gives you a written plan for what follows.